Biography
Christian is responsible for driving business development and incubation in adjacent fields and white spaces at Siemens Healthineers. Christian and his team evaluate opportunities, trigger investments in start-ups, and drive partnership projects – with a particular focus on the field of precision medicine. Christian also serves on the board of associations and start-up companies focusing on precision medicine. Christian brings more than 15 years of experience in new business development and has successfully incubated a variety of new products, developed strategies for leading global companies, and is the (co)-inventor of assorted patent families. He is driven by his passion to bridge the chasm between innovative ideas and the commercialization of new technologies.

Talk
Reimagining Oncology - Closing the Gaps between Science and Clinic
Today we see major gaps in oncology care delivery when it comes to transferring innovation from scientific discovery into clinical practice. Together with experienced industry professionals we will discuss persisting gaps along the oncology patient journey and how they can be addressed by making use of emerging trends.

Biography
Ben Gonzales serves as the leader of Business Development efforts for Biognosys in North America. With a history in mass spectrometry and proteomics Ben has been able to successfully guide the team in support of solutions in Precision Medicine and Unbiased Discovery.

Biography
Debanti leads due diligence activities on commercial opportunities of interest, and manages an international portfolio of oncology-focused industry-academic research projects.

Biography
Dr. Rangarajan Sampath is Senior Vice President and Head of Center for Innovation in Diagnostics at Siemens Healthineers, where he leads Innovation and new product development in the areas of oncology, neurology and infectious diseases. CID’s focus is to drive disruptive next generation innovation, development and commercialization of in-vitro diagnostics, automation and digital health solutions. Prior to this, Dr. Sampath was Chief Scientific Officer at Foundation for Innovative New Diagnostics (FIND), a Geneva-based non-profit organization (NGO) focused on bringing cutting edge diagnostics to low- and middle- income countries. Dr. Sampath headed FIND’s research and development organization, leading its innovation, product development and disease programs. During the COVID-19 pandemic, he led a team of researchers to set up an evaluation framework to provide independent assessment of commercially available assays to aid procurement and country prioritization decisions. He also represented FIND as a Working Group member in the Access to COVID Tools -Accelerator Diagnostics (ACT-A Dx) Partnership, co-convened by FIND and the Global Fund. From 1997-2017, Dr. Sampath served as a Volwiler Senior Research Fellow and Senior Director of R&D for the Ibis Division of Abbott. He led Ibis’ R&D efforts in infectious disease diagnostics, antimicrobial resistance diagnostics and surveillance, and was responsible for applications development, validation, data analysis and reporting for the Ibis PCR/ESI-MS based IRIDICA platform. Dr. Sampath was the co-founder of Ibis Biosciences, Inc. and a co-inventor of the IRIDICA (CE-IVD) infectious disease diagnostics platform. Dr. Sampath is a recognized leader in the field, with over 100 publications and over 40 issued patents in infectious disease diagnostics. He was an invited participant at the White House National Forum on Antibiotic Stewardship and was an active member of the AdvamedDx Industry Forum for the global commitment on developing diagnostic tests to fight AMR. He has been an invited speaker at many public forums such as at the Institute of Medicine, Infectious Diseases Society of America (IDSA) and Parenteral Drug Association (PDA). He was a key member of an FDA/PDA task force involved in defining the future of viral screening for cell substrates. Dr. Sampath most recently served for a 3-year term as a member of the Diagnostics Committee for IDSA. His research interests include sepsis, antimicrobial strategy development, pathogen discovery, fevers of unknown origin, tropical diseases, epidemiological surveillance and biothreat detection.

Talk
Improving Cancer Outcomes through Early Precision Diagnostics
Exponentially growing knowledge and precise technologies provide great opportunity for individualization of therapeutic intervention. Scalable precision diagnostics will improve disease outcomes through early detection and monitoring in cancer patients. Digital integration of data is key to achieving both. This talk will focus on combining “omics” data with imaging for comprehensive cancer care.

Biography
Isma is passionate about patient involvement in the Research & Development of innovative medicines, the life-cycle management of marketed products and is working extensively with various stakeholders to accelerate access to medicines. Prior to her current role, Isma was responsible for advancing Amgen’s expertise and leadership in Global Patient Safety & Labeling. With over 20 years of pharmaceutical industry experience, she has held various roles with increasing level of responsibility in different organizations. Prior to joining Amgen, she served as Vice President and Head of Safety Surveillance and Risk Management at Sanofi Genzyme and Executive Vice President with Pfizer Consumer Health Care. She has also worked in Clinical Development, Medical Affairs and Executive Management at Wyeth Pharmaceuticals and Eli Lilly France. Isma earned her MBA at the Massachusetts Institute of Technology, Masters in Bioethics from the U Pennsylvania and her medical degree in Psychiatry from Faculte de Medecine d’Alger.